IO Biotech (IOBT) Competitors $1.47 +0.09 (+6.52%) As of 12:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IOBT vs. TERN, ARCT, CMPX, ATXS, SNDL, GOSS, MBX, AQST, CYRX, and IVAShould you be buying IO Biotech stock or one of its competitors? The main competitors of IO Biotech include Terns Pharmaceuticals (TERN), Arcturus Therapeutics (ARCT), Compass Therapeutics (CMPX), Astria Therapeutics (ATXS), SNDL (SNDL), Gossamer Bio (GOSS), MBX Biosciences (MBX), Aquestive Therapeutics (AQST), CryoPort (CYRX), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry. IO Biotech vs. Its Competitors Terns Pharmaceuticals Arcturus Therapeutics Compass Therapeutics Astria Therapeutics SNDL Gossamer Bio MBX Biosciences Aquestive Therapeutics CryoPort Inventiva IO Biotech (NASDAQ:IOBT) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability. Do insiders & institutionals believe in IOBT or TERN? 54.8% of IO Biotech shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 2.3% of IO Biotech shares are held by insiders. Comparatively, 1.5% of Terns Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is IOBT or TERN more profitable? Terns Pharmaceuticals' return on equity of -28.81% beat IO Biotech's return on equity.Company Net Margins Return on Equity Return on Assets IO BiotechN/A -162.55% -125.08% Terns Pharmaceuticals N/A -28.81%-27.55% Which has preferable earnings & valuation, IOBT or TERN? Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIO BiotechN/AN/A-$95.49M-$1.37-1.07Terns PharmaceuticalsN/AN/A-$88.85M-$1.09-3.90 Does the media prefer IOBT or TERN? In the previous week, Terns Pharmaceuticals had 4 more articles in the media than IO Biotech. MarketBeat recorded 6 mentions for Terns Pharmaceuticals and 2 mentions for IO Biotech. Terns Pharmaceuticals' average media sentiment score of 1.34 beat IO Biotech's score of 0.93 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IO Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Terns Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer IOBT or TERN? IO Biotech presently has a consensus price target of $9.33, suggesting a potential upside of 534.92%. Terns Pharmaceuticals has a consensus price target of $15.63, suggesting a potential upside of 267.30%. Given IO Biotech's stronger consensus rating and higher possible upside, equities analysts plainly believe IO Biotech is more favorable than Terns Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IO Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more volatility and risk, IOBT or TERN? IO Biotech has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. SummaryTerns Pharmaceuticals beats IO Biotech on 8 of the 14 factors compared between the two stocks. Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IOBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOBT vs. The Competition Export to ExcelMetricIO BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$96.84M$2.90B$5.51B$8.92BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-0.9921.4026.2119.84Price / SalesN/A279.63415.30113.63Price / CashN/A41.8936.4957.06Price / Book2.077.358.005.32Net Income-$95.49M-$55.05M$3.15B$248.42M7 Day Performance-2.65%2.02%1.72%2.50%1 Month Performance-9.26%6.76%4.63%5.53%1 Year Performance24.58%4.83%35.87%19.65% IO Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOBTIO Biotech3.234 of 5 stars$1.47+6.5%$9.33+534.9%+23.2%$96.84MN/A-0.9930Gap UpTERNTerns Pharmaceuticals4.1674 of 5 stars$3.68-5.6%$15.63+324.6%-43.8%$340.61MN/A-3.3840Positive NewsARCTArcturus Therapeutics3.764 of 5 stars$12.51+1.8%$53.50+327.7%-45.1%$333.31M$152.31M-4.94180Positive NewsCMPXCompass Therapeutics3.0295 of 5 stars$2.54+5.8%$13.13+416.7%+172.9%$331.88M$850K-6.2020News CoverageAnalyst UpgradeATXSAstria Therapeutics1.8253 of 5 stars$5.61-4.3%$30.00+434.8%-41.3%$330.70MN/A-3.0030SNDLSNDL3.7985 of 5 stars$1.24-0.8%$3.63+192.3%-36.5%$328.47M$671.81M-4.282,516Positive NewsGOSSGossamer Bio3.63 of 5 stars$1.37-4.9%$7.75+465.7%+31.9%$327.32M$114.70M-5.96180MBXMBX Biosciences2.7219 of 5 stars$9.73-0.1%$37.50+285.4%N/A$325.22MN/A0.0036AQSTAquestive Therapeutics1.4137 of 5 stars$3.29+1.2%$10.14+208.3%+38.8%$322.82M$57.56M-5.58160News CoverageCYRXCryoPort2.3197 of 5 stars$6.56+3.0%$11.00+67.7%+14.4%$319.37M$228.38M-2.801,186News CoveragePositive NewsIVAInventiva3.1379 of 5 stars$3.34+1.5%$10.40+211.5%-2.0%$314.73M$9.95M0.00100 Related Companies and Tools Related Companies Terns Pharmaceuticals Competitors Arcturus Therapeutics Competitors Compass Therapeutics Competitors Astria Therapeutics Competitors SNDL Competitors Gossamer Bio Competitors MBX Biosciences Competitors Aquestive Therapeutics Competitors CryoPort Competitors Inventiva Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOBT) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.